Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion – Video abstract ID 136297 скачать в хорошем качестве

Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion – Video abstract ID 136297

Video abstract of case report paper “Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant” published in the OncoTargets and Therapy journal by Zhao Z, Song ZJ, Wang XW, et al. Abstract: ROS1 fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1 translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant, which was different from the two common SLC34A2-ROS1 fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal. Read the Case report paper here https://www.dovepress.com/response-to...